Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Commissioner Search: Pharma’s Preferred Candidate Is Gottlieb

Executive Summary

Analyst poll of 53 drug companies indicates broad support for Scott Gottlieb compared to three other known candidates for FDA Commissioner.

You may also be interested in...



Trump Slams FDA Regulations In Joint Session Of Congress

US president hit on his sentiments of faster drug approval times and deregulation, signaling FDA could be in for period of sustained criticism.

Sweeping FDA Changes Could Have “Disastrous Consequences” For Biotech Investment

Lowering the bar on drug approval standards would create a challenging environment for biotech investors, warned Jonathan Leff, a partner at the health care investment firm Deerfield, during the BIO CEO & Investor Conference.

US FDA’s Bipartisan Support May Offer Shelter From Political Winds, Former Chief Says

In the wake of 21st Century Cures legislation, next commissioner will have strong support across party lines to undertake smarter regulation aimed at improving the efficiency of the drug development process, former FDA head McClellan says.

Related Content

Topics

UsernamePublicRestriction

Register

PS119974

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel